...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinics and research in hepatology and gastroenterology >Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.
【24h】

Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.

机译：telaprevir和boceprevir在有治疗经验的患者中治疗丙型肝炎病毒感染的抗病毒活性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Around 50% of hepatitis C virus (HCV)-positive patients infected with genotype 1 are nonresponders to the combination of pegylated interferon (pegIFN) and ribavirin, including relapsers, and partial and null responders and, as such, are exposed to the risk of progression to cirrhosis and its complications, resulting in HCV-related morbidity and mortality. Repeat treatment using the same combination in such patients results in <5% viral eradication and there are no therapeutic prospects for patients who fail, as maintenance therapy has not proved efficacious. The triple association of direct-acting antivirals specific of HCV, and especially the first-generation protease inhibitors boceprevir and telaprevir, increases this percentage to around 65%, with variations according to the previous response to therapy of patients (85% of relapsers, 50% of partial responders and 30% of null responders). These encouraging results extend the therapeutic indications and costs of therapy during virological follow-up, and influence the rules of discontinuation. Information on the management of these new molecules also allows a larger number of patients to be cured and reduces the occurrence of viral resistance. Thus, the aim of the present review is to summarize the efficacy of the triple association of pegIFN, ribavirin and telaprevir or boceprevir in treatment-experienced patients who failed to respond to dual pegIFN and ribavirin therapy.
机译：感染基因型1的大约50％的丙型肝炎病毒（HCV）阳性患者对聚乙二醇化干扰素（pegIFN）和利巴韦林的组合（包括复发者），部分和无效应答者无反应，因此，他们面临着以下风险：进展为肝硬化及其并发症，导致HCV相关的发病率和死亡率。在此类患者中使用相同的组合重复治疗可导致<5％的病毒根除，并且失败的患者没有治疗前景，因为维持治疗尚未被证明是有效的。 HCV特异的直接作用抗病毒药，尤其是第一代蛋白酶抑制剂boceprevir和telaprevir的三联体，使该百分比增至约65％，根据先前对患者治疗的反应而有所不同（85％的复发者，50部分响应者的百分比，无效响应者的30％）。这些令人鼓舞的结果扩大了病毒学随访期间的治疗指征和治疗成本，并影响了停药的规则。有关这些新分子管理的信息还可以使更多的患者治愈，并减少病毒抗药性的发生。因此，本综述的目的是总结pegIFN，利巴韦林和telaprevir或boceprevir三联疗法在对pegIFN和利巴韦林双重疗法无效的治疗经验患者中的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号